title: Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease.
abstract: The clinical heterogeneity that characterizes chronic lymphocytic leukemia (CLL), with survival times ranging from months to decades, reflects its biological diversity. Our understanding of the biology of CLL has helped us identify several markers of prognostic significance, by which CLL can be differentiated into several distinct diseases. The presence of specific chromosomal abnormalities is a prognostic indicator of disease progression and survival. Conventional cytogenetic analyses have revealed chromosomal aberrations in 40-50% of patients, but the detection of abnormalities is limited by the low mitotic activity of CLL cells. Metaphase analysis has recently undergone a "revival" because the metaphase yield has been improved by stimulation of CLL cells with alternative methods. Fluorescence in situ hybridization identifies chromosomal changes in approximately 80% of patients with CLL, and comparative genomic hybridization using high-density arrays (i.e., array comparative genomic hybridization [aCGH]) enables high-resolution genome-wide scanning for detecting copy number alterations in a single hybridization. The mutational status of the immunoglobulin heavy chain variable (IGHV) genes identifies two subsets of CLL with different outcomes. Unfortunately, the determination of IGHV mutation status may not be practical in all laboratories, and for this reason characteristics that are correlated with IGHV mutation status are needed-zeta-chain associated (TCR) protein kinase 70 kDa (ZAP-70) being that most commonly used currently in routine clinical practice. Whole genome sequencing has offered new insights into the mutational status of the disease, highlighting the role of several genes previously unrelated to CLL. Of these, NOTCH1 and SF3B1 are the most frequently mutated genes that predict poor prognosis. MicroRNA alterations are also involved in the initiation and progression of CLL, and the expression levels of some microRNAs correlate with previously established prognostic markers such as IGHV mutation status or ZAP-70. In addition, both global and gene-specific aberrant DNA methylation have been observed in CLL. Aberrant methylation has been described for genes that are specifically deregulated in CLL, such as BCL2, TCL1, and ZAP-70. Expanding knowledge of aberrant methylation profiles in CLL has a potential future impact on diagnosis, prognosis, and prediction of treatment response in CLL patients.
authors.affiliation: IBSAL, IBMCC, Centro de Investigación del Cáncer, Universidad de Salamanca-CSIC, and Servicio de Hematologı´a, Hospital Clı´nico Universitario de Salamanca, Salamanca, Spain.
authors.forename: Ana E
authors.initials: AE
authors.lastname: Rodríguez-Vicente
authors.forename: Marcos González
authors.initials: MG
authors.lastname: Díaz
authors.forename: Jesús M
authors.initials: JM
authors.lastname: Hernández-Rivas
mesh_terms: D002869:Chromosome Aberrations; D020732:Cytogenetic Analysis / Q000379:methods; D019175:DNA Methylation; D018740:Genetic Heterogeneity; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000235:genetics* / Q000473:pathology; D035683:MicroRNAs / Q000235:genetics; D009154:Mutation; D010750:Phosphoproteins / Q000235:genetics; D011379:Prognosis; D000072260:RNA Splicing Factors; D051881:Receptor, Notch1 / Q000235:genetics; D017413:Ribonucleoprotein, U2 Small Nuclear / Q000235:genetics
chemical_list: D035683:MicroRNAs; C497761:NOTCH1 protein, human; D010750:Phosphoproteins; D000072260:RNA Splicing Factors; D051881:Receptor, Notch1; D017413:Ribonucleoprotein, U2 Small Nuclear; C112491:SF3B1 protein, human